Random posts

  • Phase III: 7/27/2020
  • Sniffing COVID: 6/30/2020
  • Vaccines: 5/21/2020
  • Restart: 4/26/2020
  • SARS-CoV-2: 4/13/2020
  • Work Less: 3/7/2020
  • Feel Better: 2/19/2020
  • Microbial Dx: 2/10/2020
  • Saving the Pond: 8/28/2019
  • Animal Happiness: 11/10/2017
  • Cities of The Future: 5/17/2015

    Blog Archives

  • Vaccines: Precision & Performance

        Thursday, May 21, 2020
    Could the development of novel vaccine candidates be better directed and predicted based on the genetic history of an individual and/or a genetically similar sub-population?

    Until the late 1990s, vaccines were developed by an empirical method based on the “Isolate–Inactivate–Inject” paradigm.  Traditional vaccinology relied on empirical screening of a few candidates at a time - a weakened or inactivated virus particle or a microbial party - such as a viral spike protein responsible for penetrating inside the cell or a bacterial toxin.

    But vaccines are amenable to and should be personalized, based on results of high throughput “omics” technologies-based diagnostics. 

    Vaccines ability to provide immunity depends on polymorphisms in genes influencing/regulating infection process or immune response. Next-generation high throughput sequencing technologies (NGS) that became available at the onset of this century enabled identification of mutations targetable by individualized vaccines. Improvements in mRNA delivery had a major impact on mRNA therapeutics and the development of new cancer vaccines.


    ... Read more ...